This systematic review and meta-analysis of nine retrospective cohort studies provides the most up-to-date evidence that SGLT2 inhibitors have a beneficial effect on mortality and reducing cardiotoxicity in patients with cancer and type 2 diabetes mellitus undergoing cancer therapy. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.